KontRASt-03: A Phase Ib/II multicenter open-label platform study of JDQ443 with select combinations in patients with advanced solid tumor harboring the KRAS G12C mutation

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Advanced Solid Tumor Harboring Kras G12c Mutation
  • Age: Between 18 Year(s) - 100 Year(s)
  • Gender: Female
  • Other Inclusion Criteria:
    1. Have solid tumors with a specific genetic mutation called KRAS G12C, which have spread to other parts of the body or could not be removed through surgery.
    2. Have a type of advanced colorectal cancer with a specific genetic mutation called KRAS G12C, which has spread to other parts of the body or could not be removed through surgery and have already received chemotherapy treatments that include fluropyrimidine, oxaliplatin, and irinotecan.
    3. Need to have either tissue samples from a previous biopsy that could be used to confirm the presence of the KRAS G12C mutation or be willing to undergo a new biopsy if no tissue samples were available.

You may not be eligible for this study if the following are true:

    1. A tumor that has a specific genetic mutation (other than KRAS G12C) that could be treated with an approved targeted therapy.
    2. A brain tumor that has spread to other parts of the brain or to the membranes surrounding the brain (leptomeningeal disease) and is causing symptoms.
    3. Have received a bone marrow or solid organ transplant from a donor (allogeneic) in the past.



If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.